1.A Life-Threatening Case of Infective Endocarditis Complicated by Destruction of the Aortic Valve and Embolism of the Left Anterior Descending Coronary Artery
Hirohito TERADA ; Taishi KAWAHATA ; Keisuke NAKAMURA ; Hirofumi NAKAGAWA ; Hiroshi OKUYAMA ; Akihiro NABUCHI
Japanese Journal of Cardiovascular Surgery 2023;52(1):18-23
		                        		
		                        			
		                        			A 39-year-old man with fever and dyspnea from 3 days earlier was taken to the emergency room. He was diagnosed with infective endocarditis because echocardiography showed a mobile 10 mm-sized vegetation on the aortic valve and severe aortic regurgitation. Acute coronary syndrome was negative because the tests at the first visit did not show an increase in myocardial deviation enzymes or a decrease in wall motion. However, his hemodynamics deteriorated during the same day, so he underwent emergency surgery. The left and right leaflets and the right aortic annulus were highly destroyed, and the aortic annulus was reconstructed with his pericardium and the valve was replaced by a mechanical valve. After declamping of the aorta, the wall motion of the left ventricle was extremely reduced, and the cardiopulmonary bypass(CPB) was not able to be withdrawn. Since the left anterior descending (LAD) coronary artery may have been occluded by vegetation, we added bypass surgery to the LAD under cardiac arrest using a saphenous vein graft. After the bypass surgery, the wall motion of the left ventricle improved, and we were able to withdraw the CPB. Though he developed a cerebral infarction as a complication and required long-term rehabilitation, he was able to be discharged from the hospital 74 days after the operation. We evaluated the coronary arteries after his discharge and found an occlusion that was thought to be due to vegetation scattered in the LAD. No preoperative coronary artery evaluation was performed, however, the graft was anastomosed to the distal side of the LAD occlusion. Currently, 3 years and 2 months have passed and the infection has not recurred.
		                        		
		                        		
		                        		
		                        	
2.Development of a Training Program on the Proper Use of Over-the-Counter Drugs for Pharmacy Pharmacists
Chie HIRAOKA ; Keiko (Sasaki) AKAGAWA ; Yoshiaki FUJITA ; Yuki ODANAKA ; Atsuhiko SANO ; Mika NAGANUMA ; Tetsuya OGINO ; Hajime KATO ; Akihiro NAKAMURA
Japanese Journal of Social Pharmacy 2022;41(2):155-166
		                        		
		                        			
		                        			The importance of promoting self-medication is increasing, and the active participation of pharmacies is required to support this. We developed a training program based on the Attention, Relevance, Confidence, and Satisfaction (ARCS) model, which is a motivational design process to train pharmacists who support the proper use of OTC drugs, and for insurance pharmacists who usually perform dispensing work. In the six months of training, we conducted six sessions for insurance pharmacists on the subject of colds and constipation. In addition to conducting lectures and exercises on OTC drugs, we provided pharmacists with an opportunity to practice the training content during their daily work, and discuss solutions to the problems that they encountered. Of the eight participants who attended all workshops and were part of the final evaluation, seven provided OTC drugs after considering whether it was necessary to provide them. A total of six advised patients who came to the pharmacy to have their prescription medications dispensed that there were OTC medications that they should be careful about taking. These results suggest the usefulness of this training program based on the ARCS motivational design model.
		                        		
		                        		
		                        		
		                        	
3.Reduction in HPV 16/18 prevalence among young women following HPV vaccine introduction in a highly vaccinated district, Japan, 2008–2017
Akihiro KARUBE ; Fumiko SAITO ; Enami NAKAMURA ; Akihiro SHITARA ; Natsuki ONO ; Megumi KONNO ; Daisuke TAMURA ; Daisuke NAGAO
Journal of Rural Medicine 2019;14(1):48-57
		                        		
		                        			
		                        			Objective: Human papillomavirus (HPV) vaccination was introduced in Japan in April 2013, as a national immunization program for girls aged 12–16 years, after an initial introduction in 2010 as a public-aid program for girls aged 13–16 years. The Yuri-Honjo district had the highest vaccine coverage among women aged 17–51 years in 2017, due to the original public-aid program. The aim of this study was to evaluate the differences in the vaccine types of HPV16/18 infections between 2008–2012 (pre-vaccine era) and 2013–2017 (vaccine era).Materials and Methods: We evaluated whether HPV vaccination was associated with a decrease in the prevalence of HPV16/18 and high-risk HPV and the incidence of HPV-associated cervical lesions. A total of 1,342 women aged 18–49 years, covering both the pre-vaccine and vaccine eras, who visited Yuri Kumiai General Hospital and underwent HPV genotype tests from June 2008 to December 2017 were compared.Results: Among women aged 18–24 years with higher vaccine coverage (68.2%), the prevalence of HPV16/18 and high-risk HPV decreased from 36.7% and 69.4%, respectively, in the pre-vaccine era to 5.8% and 50.0%, respectively, in the vaccine era (p=0.00013 and p=0.047, respectively). Among those with cervical intraepithelial neoplasia grade 2− and grade 2+, HPV16/18 prevalence decreased from 30.0% to 2.7% (p=0.0018) and from 81.8% to 36.4% (p=0.030), respectively. In this age group, the rate of HPV16/18 positivity decreased significantly. Among age groups with lower vaccine coverage, HPV prevalence did not significantly differ between the two eras.Conclusion: The prevalence of HPV16/18 and high-risk HPV significantly decreased in women aged 18–24 years, most of whom were vaccinated. HPV vaccination effectively reduced the prevalence of HPV16/18 infections in the Yuri-Honjo district.
		                        		
		                        		
		                        		
		                        	
4.Benefits of Combining Cervical Cancer Screening with Human Papillomavirus Testing and Cytology
Akihiro KARUBE ; Fumiko SAITO ; Akihiro SHITARA ; Enami NAKAMURA ; Katsuhiro KANAMORI ; Mizuki TAKAHASHI ; Kozue IKEDA ; Yuka KAWANA
Journal of the Japanese Association of Rural Medicine 2019;68(1):18-25
		                        		
		                        			
		                        			This study sought to demonstrate the benefits of conducting cervical cytology and human papillomavirus (HPV) testing in our cervical cancer screening program and was conducted between April 2012 and March 2017 in the Yuri-Honjo district of Akita Prefecture. A total of 3581 women aged 20-49 years underwent this combined screening for 5 years. Of these, 10.3% (369/3581) tested positive for HPV, and 433 women were initially diagnosed as positive for atypical squamous cells of undetermined significance and/or positive for HPV. Of those, 342 women (79.0%) underwent cervical biopsy, among whom 62 (18.1%) were diagnosed as positive for cervical intraepithelial neoplasia (CIN)2+. Of 204 women who were positive for HPV but showed no abnormalities in cytology, 24 women (11.8%) were positive for CIN2+ and 6 women were positive for CIN3+. Conventional cytology (Pap test) detected only 0.58% of the examinees positive for CIN2+ in Akita Prefecture, whereas our combined screening involving a Pap test and HPV testing detected 1.73% of the examinees (P<0.0001). We recommend HPV testing be used in combination with the Pap test to improve cervical cancer screening and accurately identify CIN2/3 disease.
		                        		
		                        		
		                        		
		                        	
5.Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial.
Tadakazu HISAMATSU ; Reiko KUNISAKI ; Shiro NAKAMURA ; Tomoyuki TSUJIKAWA ; Fumihito HIRAI ; Hiroshi NAKASE ; Kenji WATANABE ; Kaoru YOKOYAMA ; Masakazu NAGAHORI ; Takanori KANAI ; Makoto NAGANUMA ; Hirofumi MICHIMAE ; Akira ANDOH ; Akihiro YAMADA ; Tadashi YOKOYAMA ; Noriko KAMATA ; Shinji TANAKA ; Yasuo SUZUKI ; Toshifumi HIBI ; Mamoru WATANABE
Intestinal Research 2018;16(3):494-498
		                        		
		                        			
		                        			No abstract available.
		                        		
		                        		
		                        		
		                        			Crohn Disease*
		                        			;
		                        		
		                        			Food, Formulated*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Infliximab*
		                        			
		                        		
		                        	
6.Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease.
Shinichiro SHINZAKI ; Toshimitsu FUJII ; Shigeki BAMBA ; Maiko OGAWA ; Taku KOBAYASHI ; Masahide OSHITA ; Hiroki TANAKA ; Keiji OZEKI ; Sakuma TAKAHASHI ; Hiroki KITAMOTO ; Kazuhito KANI ; Sohachi NANJO ; Takeshi SUGAYA ; Yuko SAKAKIBARA ; Toshihiro INOKUCHI ; Kazuki KAKIMOTO ; Akihiro YAMADA ; Hisae YASUHARA ; Yoko YOKOYAMA ; Takuya YOSHINO ; Akira MATSUI ; Misaki NAKAMURA ; Taku TOMIZAWA ; Ryosuke SAKEMI ; Noriko KAMATA ; Toshifumi HIBI
Intestinal Research 2018;16(4):609-618
		                        		
		                        			
		                        			BACKGROUND/AIMS: The influences of Helicobacter pylori eradication therapy on the disease course of inflammatory bowel disease (IBD) are still unclear. We therefore conducted a multicenter, retrospective cohort study to evaluate the safety of H. pylori eradication therapy for IBD patients. METHODS: IBD patients with H. pylori eradication from 2005 to 2015 (eradication group) and control patients (non-eradication group; 2 paired IBD patients without H. pylori eradication matched with each eradicated patient) were included. IBD exacerbation (increased/additional IBD drug or IBD-associated hospitalization/surgery) and disease improvement based on the physicians’ global assessment were investigated at baseline, and at 2 and 6 months after eradication or observation. RESULTS: A total of 429 IBD (378 ulcerative colitis, 51 Crohn’s disease) patients, comprising 144 patients in the eradication group and 285 patients in the non-eradication group, were enrolled at 25 institutions. IBD exacerbation was comparable between groups (eradication group: 8.3% at 2 months [odds ratio, 1.76; 95% confidence interval, 0.78–3.92; P=0.170], 11.8% at 6 months [odds ratio, 1.60; 95% confidence interval, 0.81–3.11; P=0.172]). Based on the physicians’ global assessment at 2 months, none of the patients in the eradication group improved, whereas 3.2% of the patients in the non-eradication group improved (P=0.019). Multivariate analysis revealed that active disease at baseline, but not H. pylori eradication, was an independent factor for IBD exacerbation during 2 months’ observation period. The overall eradication rate was 84.0%–comparable to previous reports in non-IBD patients. CONCLUSIONS: H. pylori eradication therapy does not alter the short-term disease activity of IBD.
		                        		
		                        		
		                        		
		                        			Clarithromycin
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Colitis, Ulcerative
		                        			;
		                        		
		                        			Helicobacter pylori*
		                        			;
		                        		
		                        			Helicobacter*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases*
		                        			;
		                        		
		                        			Metronidazole
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
7.NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases.
Toshiyuki SATO ; Tetsuya TAKAGAWA ; Yoichi KAKUTA ; Akihiro NISHIO ; Mikio KAWAI ; Koji KAMIKOZURU ; Yoko YOKOYAMA ; Yuko KITA ; Takako MIYAZAKI ; Masaki IIMURO ; Nobuyuki HIDA ; Kazutoshi HORI ; Hiroki IKEUCHI ; Shiro NAKAMURA
Intestinal Research 2017;15(3):328-337
		                        		
		                        			
		                        			BACKGROUND/AIMS: Recent genome-wide analyses have provided strong evidence concerning adverse events caused by thiopurine drugs such as azathioprine (AZA) and 6-mercaptopurine. The strong associations identified between NUDT15 p.Arg139Cys and thiopurine-induced leukopenia and severe hair loss have been studied and confirmed over the last 2 years. However, other coding variants, including NUDT15 p.Val18_Val19insGlyVal, NUDT15 p.Val18Ile, and FTO p.Ala134Thr, and a noncoding variation in RUNX1 (rs2834826) remain to be examined in detail in this respect. Therefore, we investigated the correlation between these adverse events and the 5 recently identified variants mentioned above among Japanese patients with inflammatory bowel diseases (IBD). METHODS: One hundred sixty thiopurine-treated patients with IBD were enrolled. Genotyping was performed using TaqMan SNP Genotyping Assays or Sanger sequencing. RESULTS: None of the 5 variants were associated with gastrointestinal intolerance to AZA. However, NUDT15 p.Arg139Cys was significantly associated with the interval between initiation and discontinuation of AZA among patients with gastrointestinal intolerance. This variant was strongly associated with early (<8 weeks) and late (≥8 weeks) leukopenia and severe hair loss. Moreover, it correlated with the interval between initiation of thiopurine therapy and leukopenia occurrence, and average thiopurine dose. NUDT15 p.Val18_Val19insGlyVal, NUDT15 p.Val18Ile, FTO p.Ala134Thr, and RUNX1 rs2834826 exhibited no significant relationship with the adverse events examined. CONCLUSIONS: Of the 5 variants investigated, NUDT15 p.Arg139Cys had the strongest impact on thiopurine-induced leukopenia and severe hair loss; therefore, its genotyping should be prioritized over that of other variants in efforts to predict these adverse events in Japanese patients with IBD.
		                        		
		                        		
		                        		
		                        			6-Mercaptopurine
		                        			;
		                        		
		                        			Asian Continental Ancestry Group*
		                        			;
		                        		
		                        			Azathioprine
		                        			;
		                        		
		                        			Clinical Coding
		                        			;
		                        		
		                        			Hair
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases*
		                        			;
		                        		
		                        			Leukopenia
		                        			
		                        		
		                        	
8.Aortic Arch Aneurysm 7 Years after Aortic Root Replacement in a Patient of Loeys-Dietz Syndrome
Jun Hayashi ; Seigo Gomi ; Tetsuro Uchida ; Azumi Hamasaki ; Yoshinori Kuroda ; Atsushi Yamashita ; Ken Nakamura ; Daisuke Watanabe ; Shingo Nakai ; Akihiro Kobayashi ; Mitsuaki Sadahiro
Japanese Journal of Cardiovascular Surgery 2017;46(4):157-160
A 14-year-old women who had a history of aortic root replacement at 7 years old admitted our hospital due to dilatation of aortic arch aneurysm. Loeys-Dietz syndrome was diagnosed when she was 10 years old. Computed tomography showed 70 mm proximal arch aneurysm. Operative findings revealed brachiocephalic artery and left common carotid artery branched from aneurysm. Partial arch replacement was performed and distal anastomosis was made between left common carotid artery and left subclavian artery. Close observation by CT regularly is necessary and undergo aortic repair not to miss the timing of surgery.
9.Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial.
Koji AKEDA ; Kohshi OHISHI ; Koichi MASUDA ; Won C. BAE ; Norihiko TAKEGAMI ; Junichi YAMADA ; Tomoki NAKAMURA ; Toshihiko SAKAKIBARA ; Yuichi KASAI ; Akihiro SUDO
Asian Spine Journal 2017;11(3):380-389
		                        		
		                        			
		                        			STUDY DESIGN: Preliminary clinical trial. PURPOSE: To determine the safety and initial efficacy of intradiscal injection of autologous platelet-rich plasma (PRP) releasate in patients with discogenic low back pain. OVERVIEW OF LITERATURE: PRP, which is comprised of autologous growth factors and cytokines, has been widely used in the clinical setting for tissue regeneration and repair. PRP has been shown in vitro and in vivo to potentially stimulate intervertebral disc matrix metabolism. METHODS: Inclusion criteria for this study included chronic low back pain without leg pain for more than 3 months; one or more lumbar discs (L3/L4 to L5/S1) with evidence of degeneration, as indicated via magnetic resonance imaging (MRI); and at least one symptomatic disc, confirmed using standardized provocative discography. PRP releasate, isolated from clotted PRP, was injected into the center of the nucleus pulposus. Outcome measures included the use of a visual analog scale (VAS) and the Roland-Morris Disability Questionnaire (RDQ), as well as X-ray and MRI (T2-quantification). RESULTS: Data were analyzed from 14 patients (8 men and 6 women; mean age, 33.8 years). The average follow-up period was 10 months. Following treatment, no patient experienced adverse events or significant narrowing of disc height. The mean pain scores before treatment (VAS, 7.5±1.3; RDQ, 12.6±4.1) were significantly decreased at one month, and this was generally sustained throughout the observation period (6 months after treatment: VAS, 3.2±2.4, RDQ; 3.6±4.5 and 12 months: VAS, 2.9±2.8; RDQ, 2.8±3.9; p<0.01, respectively). The mean T2 values did not significantly change after treatment. CONCLUSIONS: We demonstrated that intradiscal injection of autologous PRP releasate in patients with low back pain was safe, with no adverse events observed during follow-up. Future randomized controlled clinical studies should be performed to systematically evaluate the effects of this therapy.
		                        		
		                        		
		                        		
		                        			Cytokines
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			In Vitro Techniques
		                        			;
		                        		
		                        			Intercellular Signaling Peptides and Proteins
		                        			;
		                        		
		                        			Intervertebral Disc
		                        			;
		                        		
		                        			Intervertebral Disc Degeneration
		                        			;
		                        		
		                        			Leg
		                        			;
		                        		
		                        			Low Back Pain*
		                        			;
		                        		
		                        			Magnetic Resonance Imaging
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Metabolism
		                        			;
		                        		
		                        			Outcome Assessment (Health Care)
		                        			;
		                        		
		                        			Platelet-Rich Plasma*
		                        			;
		                        		
		                        			Regeneration
		                        			;
		                        		
		                        			Visual Analog Scale
		                        			
		                        		
		                        	
10.A survey of home care provided by hospitals and clinics in an urban area of Japan
Masakatsu Shimizu ; Takuya Shinjo ; Shigeyuki Kobayashi ; Shoji Hamano ; Toru Okano ; Hiroomi Nakamura ; Akihiro Ishikawa ; Masako Sekimoto ; Hiroyuki Makimura ; Akira Honjo ; Kobe Medical Association Home Care Group
Palliative Care Research 2015;10(1):301-305
		                        		
		                        			
		                        			Objective:The aim of this study was to investigate the current status of home care provided by hospitals and clinics in Kobe City. Methods:In July 2013 a survey was mailed to a cross-section of all clinics and hospitals in Kobe City. Results:Questionnaires were sent to 1,589 clinics and hospitals and 899(57%)responded. Regular and urgent home visits by doctors were provided by 50% and 65% of respondents, respectively. End-of-life care for dying patients at home and in nursing homes was provided by 31% and 18% of respondents, respectively. The average time spent on home visits was 2.3±1.7 days per week. Care for cancer patients, participation in national palliative care lectures, and holding a discussion at the admitting hospital before discharge for home care, were performed by 23%, 7.0%, and 6.9% of respondents, respectively. Conclusion:The majority of hospitals and clinics in Kobe City provided home care.
		                        		
		                        		
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail